GSK PLC 2016 AR2
The report highlights GSK's strong performance in 2016, with Group turnover increasing by 6% CER to #27.9 billion, driven by Pharmaceuticals, Vaccines, and Consumer Healthcare. The company achieved significant pipeline progress with four major regulatory filings, including the Shingrix shingles vaccine and Closed Triple therapy for COPD. In responsible business, GSK ranked first in the Access to Medicine Index for the fifth consecutive time and reduced its operational carbon emissions by 18% since 2010. Additionally, the company expanded its graduated approach to patents and intellectual property to improve medicine access in developing countries.
Company: GSK PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2016
Type: AR2
Pages: 288
Back to company
GSK PLC
Annual Report
The report highlights GSK's strong performance in 2016, with Group turnover increasing by 6% CER to #27.9 billion, driven by Pharmaceuticals, Vaccines, and Consumer Healthcare. The company achieved significant pipeline progress with four major regulatory filings, including the Shingrix shingles vaccine and Closed Triple therapy for COPD. In responsible business, GSK ranked first in the Access to Medicine Index for the fifth consecutive time and reduced its operational carbon emissions by 18% since 2010. Additionally, the company expanded its graduated approach to patents and intellectual property to improve medicine access in developing countries.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees